C75 trans

Catalog No.S8915 Synonyms: trans-C75, (±)-C75

For research use only.

C75 trans (trans-C75, (±)-C75) is a novel, potent synthetic inhibitor of fatty acid synthase (FAS/FASN) with IC50 of 35 μM and 50 μM in clonogenic assays and spheroid growth assay, respectively. C75 is used as a tool for studying fatty acid synthesis in metabolic disorders and cancer.

C75 trans Chemical Structure

CAS No. 191282-48-1

Selleck's C75 trans has been cited by 2 Publications

Purity & Quality Control

Choose Selective Fatty Acid Synthase Inhibitors

Biological Activity

Description C75 trans (trans-C75, (±)-C75) is a novel, potent synthetic inhibitor of fatty acid synthase (FAS/FASN) with IC50 of 35 μM and 50 μM in clonogenic assays and spheroid growth assay, respectively. C75 is used as a tool for studying fatty acid synthesis in metabolic disorders and cancer.
Targets
FASN [1]
(clonogenic assay)
FASN [1]
(spheroid growth assay)
35 μM 50 μM
In vitro

C75 is toxic to prostate cancer cells. C75 reduces cell migration, while enhances radiation-induced clonogenic kill and enhances the spheroid growth delay induced by radiation exposure. Apoptosis induction by radiation exposure is enhanced by C75 treatment.[1] C75 inhibits fatty acid synthesis and growth of established cancer cell lines from neu-N transgenic mice. C75 reduces the proliferation and expression of FAS, neu, and related genes in mammary epithelium.[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MA104 NX\wcINxSW62aY\pdoFtKGG|c3H5 MVuyOEBpenN? NULub5lLSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhWm:2YY\pdpV{KFODMUGgbY4hVUFzMESgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYLhcEBz\XCuaXPheIlwdiCjZoTldkAzPCCqcoOgZpkhcW2vdX7v[ox2d3Knc3PlcpQh[XO|YYmgZY5lKFenc4Tldo4h[myxdITpcoch[W6jbInzbZMtKEWGNUCgQUAzOS5{IN88UU4> M3fiV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{[1OFEyLz5{MkO2OVQyOTxxYU6=
MA104 M4\IR2N6fG:2b4jpZ4l1gSCjc4PhfS=> NFrSO4EzPCCqcoO= M135b2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xbnvlfUBOSTFyNDDj[YxteyCjZoTldkAzPCCqcoOsJHRFPTBiPTCyPE42KM7:TT6= NIXQVI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2OVQyOSd-MkKzOlU1OTF:L3G+
A375 M1Xrd2Z2dmO2aX;uJIF{e2G7 NXHFT|ZIUW6qaXLpeIlwdiCxZjDGRXNPKGmwIHj1cYFvKEF|N{WgZ4VtdHNuIFnDOVAhRSB|Mj60N{DPxE1w Ml\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5Mk[wO|coRjJzN{K2NFc4RC:jPh?=
KB NFLme|hEgXSxdH;4bYNqfHliYYPzZZk> M{LaTmN6fG:2b4jpZ4l1gSCrbjDoeY1idiCNQjDj[YxteyxiSVO1NEA:KDN4LkWg{txONg>? MlHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3MESxOVYoRjJzNUC0NVU3RC:jPh?=
In vivo

C75 inhibits fatty acid synthesis and in vivo mammary cancer development. C75 treatment prevents mammary cancer development and retards mammary development in neu-N transgenic mice.[2]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: PC3 cells, LNCaP cells
  • Concentrations: 5 μM, 25 μM, 35 μM, 50 μM
  • Incubation Time: 3 h, 6 h, 24 h
  • Method:

    PC3 cells are seeded in 25 cm2 flasks at 105 cells/flask. When cultures are in exponential growth phase, media is removed and replaced with fresh drug-containing media. Cells are then incubated for 24 h at 37℃ in 5% CO2. To determine optimal sequencing of therapeutic agents, three different combination treatment schedules are assessed: 1. radiation and C75 administered simultaneously; 2. radiation administered 24 h before C75; and 3. radiation administered 24 h after C75. After treatment, cells are seeded for clonogenic survival assay.

Animal Research:

[2]

  • Animal Models: neu-N transgenic mice, FVB/N mice
  • Dosages: 30mg/kg
  • Administration: IP

Solubility (25°C)

In vitro

DMSO 51 mg/mL
(200.53 mM)
Water Insoluble
Ethanol ''26 mg/mL

Chemical Information

Molecular Weight 254.32
Formula

C14H22O4

CAS No. 191282-48-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCCCCCC1C(C(=C)C(=O)O1)C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy C75 trans | C75 trans supplier | purchase C75 trans | C75 trans cost | C75 trans manufacturer | order C75 trans | C75 trans distributor